AstraZeneca PLC (NASDAQ: AZN) announced on Monday that its Phase III LATIFY clinical trial evaluating ceralasertib in ...

Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

AstraZeneca’s combination therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) has failed to meet ...

Susan Galbraith, AstraZeneca’s executive vice president for oncology haematology R&D, discussed the setback in a statement. Galbraith said the goal was to “reinvigorate the immune response of patients ...

British pharma AstraZeneca (LSE: AZN) said a Phase III study of ceralasertib combined with Imfinzi (durvalumab) failed to ...

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...

"Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumours stopped ...

AstraZeneca’s LATIFY phase III trial of ceralasertib plus Imfinzi in previously treated advanced NSCLC fails to meet primary endpoint: Cambridge, UK Tuesday, December 23, 2025, ...

Investing.com -- AstraZeneca PLC (NASDAQ:AZN) announced Monday that its LATIFY Phase III trial of ceralasertib failed to meet its primary endpoint in non-small cell lung cancer (NSCLC).

Investing.com -- AstraZeneca PLC (ST:AZN) announced Monday that its LATIFY Phase III trial of ceralasertib in combination ...